FDA Authorizes Booster Dose of Novavax COVID-19 Vaccine, Adjuvanted
The booster dose elicited robust antibody responses comparable to or exceeding levels associated with the efficacy data in the primary series of the vaccine.
The booster dose elicited robust antibody responses comparable to or exceeding levels associated with the efficacy data in the primary series of the vaccine.
The Moderna bivalent vaccine is authorized for children age 6 and older, and the Pfizer-BioNTech vaccine is authorized for children age 5 and older.
Exposure to PM2.5 and NO2 are linked to an increased risk of COVID-19-related hospitalization, regardless of vaccination status.
Researchers evaluated the anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients with B-cell malignancies in a real-world setting.
Death rates could peak at more than 1000 per day during the winter if nothing changes.
The 30-day mortality rate was higher before the availability of vaccines, and the use of monoclonal antibodies alone or in combination with antivirals was associated with a lower risk of death.
NCCN has updated its recommendations on COVID-19 vaccination to include advice about bivalent vaccines, vaccinating immunocompromised children, and more.
mRNA-1273.214 elicits more neutralizing antibodies against omicron subvariants than does mRNA-1273.
Public health officials expect demand for the new booster to surge in the next few weeks.
While supplies of the updated Pfizer booster shot appear to be plentiful, some pharmacies have reported not having enough of the updated Moderna vaccine.